3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Status
Completed
4
Recruiting
3
Terminated
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Pituitary Neoplasms
1
Growth Hormone-Secreting Pituitary Adenoma
1
Acromegaly
1
Interventions
Cisplatin
129
Radiotherapy
94
Carboplatin
82
Fluorouracil
77
Paclitaxel
76
Cyclophosphamide
76
Gemcitabine
71
Capecitabine
66
Docetaxel
64
Doxorubicin
59
Oxaliplatin
57
Etoposide
57
Leucovorin
48
Vincristine
46
Chemotherapy, Adjuvant
42
Cytarabine
38
Dexamethasone
35
Drug Therapy
33
Bevacizumab
30
Epirubicin
29
Pemetrexed
27
Neoadjuvant Therapy
26
Irinotecan
25
Tamoxifen
24
Prednisone
23
Methotrexate
21
Rituximab
19
Vinorelbine
18
Radiotherapy, Intensity-Modulated
18
Peripheral Blood Stem Cell Transplantation
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Unknown
×
lanreotide
×
Clear all
NCT03439709
2018-03-01
MERGE
Samsung Medical Center
Phase 3
Unknown
90 enrolled